However, despite the presence of significant Aβ and tau pathology, and the increased rate of cognitive decline ante-mortem in the A + T + group, final visit dementia diagnosis was low (35.8%), suggesting that even with high levels of mixed pathologies, progression to clinically classified dementia is not inevitable prior to death. The gene discussed is MAPT; the disease is dementia.